Hearing News Watch

Registration is now open for exhibitors at the 69th International Congress of Hearing Aid Acousticians (EUHA), taking place from 22–24 October 2025 in Nuremberg. As of 12 February 2025, companies can secure exhibition space at the event via www.ausstellung-euha.org/en. On the first day of registration alone, more than 20 companies confirmed their participation. New Exhibition Hall & Expanded EUHA Live

MONTPELLIER, FRANCE — Sensorion (FR0012596468 – ALSEN), a clinical-stage biotechnology company specializing in novel therapies for hearing loss, announced that the Data Monitoring Committee (DMC) has recommended the continuation of the Audiogene Phase 1/2 clinical trial of SENS-501, a gene therapy program aimed at treating congenital deafness caused by OTOF (otoferlin) gene mutations. The DMC’s recommendation follows a review of

SEATTLE, WASHINGTON – Sound Pharmaceuticals will present new preclinical and clinical data on SPI-1005 at the upcoming Association for Research in Otolaryngology (ARO) MidWinter Meeting in Orlando, FL. The company will deliver four presentations highlighting advancements in hearing loss and tinnitus research, including findings on ebselen’s potential to reverse noise-induced tinnitus and SPI-1005’s efficacy in Meniere’s disease treatment. Presentations at

EDINBURGH, UK  – New insights from Hearing Diagnostics suggest that younger adults may be experiencing unexpected difficulties with central auditory processing—potentially linked to modern listening habits such as near constant usage of headphones and personal listening devices. While piloting its novel spatial-hearing-based screening technology, the company discovered that adults aged under 30 often struggle with the spatial hearing task, despite

Stress is a well-known factor influencing mental health, but its impact extends beyond psychiatric disorders. It can also reshape the way we perceive the world, from heightened sensitivity to noise to an increased awareness of irritating textures and odors. A recent study published in PLOS Biology sheds light on how repeated stress alters auditory processing in mice, offering new insights

MONTPELIER, VERMONT – Nano Hearing Aids has announced the resolution of a 2022 lawsuit filed by the State of Vermont related to allegations of consumer protection violations. The claims were tied to the company’s prior ownership under Charles Crawford and primarily concerned practices before the company was acquired by its current owners. The resolution marks a significant milestone for Nano

WASHINGTON, D.C. – Otolith Labs, a medical technology company developing prescription medical devices for vestibular disorders, has announced findings from an exploratory user study evaluating the impact of vestibular stimulation technology on cybersickness during virtual reality (VR) experiences. The study results indicate that subjects using Otolith technology reported lower nausea levels and longer VR engagement durations compared to those without

MILAN, ITALY – Amplifon, a global leader in hearing care solutions and parent company of Miracle-Ear, has launched “Endless Love,” a special communication initiative for Valentine’s Day. The campaign emphasizes the role of hearing well in maintaining meaningful relationships and experiencing emotions fully. The campaign features an image of a senior couple walking and embracing, accompanied by the message: “The

EDEN PRAIRIE, MINNESOTA – Starkey has collaborated with researchers at Stanford University to evaluate its Balance Assessment feature, a technology available with Edge AI. A recent peer-reviewed study, published in Otology & Neurotology, examines the findings of this research, contributing to the ongoing exploration of balance assessment in hearing technology. Falls are a leading cause of injury among older adults,

HEPPENHEIM & BERLIN, GERMANY – There is currently no globally approved drug for the treatment of sudden hearing loss, a condition that affects thousands of individuals each year. However, AudioCure Pharma, a Berlin-based biopharmaceutical company, is advancing research on AC102, an innovative drug candidate that has shown promising results in preclinical and Phase 1 clinical studies. In a significant development,